Notably, the correlation in the levels of these two proteins greatly contributes to an important role in gastric tumorigenic responses, and specific targeting of PRMT1-catalyzed arginine methylation of c-Fos could become a potential new therapeutic strategy for GC. The gene discussed is PRMT1; the disease is gastric cancer.